A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Received and Responded to GSK3228836 in a Previous Treatment Study
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Bepirovirsen (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms B-Sure
- Sponsors GlaxoSmithKline; GSK
- 29 Feb 2024 According to GSK media release, US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, based on data from the phase IIb trials B-Clear and B-Sure
- 14 Nov 2023 Results (n=17) assessing data on the durability of response in Not-on-NA complete responders (CRs) and partial responders (PRs) who entered B-Sure presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results (n=44) assessing data on durability of response in On-NA complete responders and partial responders (PRs) who entered B-Sure trial presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases